Shares of Medicure Inc. (CVE:MPH – Get Free Report) were up 3.5% during trading on Friday. The company traded as high as C$4.00 and last traded at C$3.83. Approximately 23,050 shares traded hands during mid-day trading, an increase of 394% from the average session volume of 4,670 shares. The stock had previously closed at C$3.70.
Medicure Price Performance
The company has a debt-to-equity ratio of 8.32, a quick ratio of 1.28 and a current ratio of 0.89. The stock’s 50 day simple moving average is C$3.51 and its two-hundred day simple moving average is C$1.82. The firm has a market capitalization of C$39.97 million, a PE ratio of -5.32 and a beta of 1.02.
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Further Reading
- Five stocks we like better than Medicure
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
